HospiMedica: AI-Based Predictive Analytics Platform Receives FDA Emergency Use Authorization in Support of COVID-19 Patients

Developed by CLEW (Netanya, Israel), CLEW-ICU allows healthcare providers to use predictive screening information to help identify patients with an increased likelihood of being diagnosed with respiratory failure or hemodynamic instability. The AI-based algorithms are machine-learning models trained to identify respiratory failure and or hemodynamic instability hours in advance. This allows for additional evaluation and potentially early intervention, planning, resource management. from HospiMedica: AI-Based Predictive Analytics Platform Receives FDA Emergency Use Authorization in Support of COVID-19 Patients

Healthcare IT News: FDA issues emergency use authorization for COVID-19 predictive screening tool

Research has shown that severe respiratory failure related to interstitial pneumonia in both lungs is among the highest contributors to COVID-19 mortality rates. Early detection can allow for faster intervention and treatment, including via mechanical ventilation. It can also enable care teams to strategize about resource use – vital for capacity management. from Healthcare IT News: FDA issues emergency use authorization for COVID-19 predictive screening tool

NY Post: FDA approves system to warn doctors before coronavirus patients deteriorate

The hospital system made by CLEW — a company based in Netanya that predicts life-threatening medical complications — has helped to keep the computer and telemedicine networks at two major Israeli hospitals running during the coronavirus pandemic, the Times of Israel reported. from NY Post: FDA approves system to warn doctors before coronavirus patients deteriorate

ILTV: Interview with CLEW’s CEO, Gal Salomon

CLEW Receives FDA Emergency Use Authorization (EUA) for Its Predictive Analytics Platform in Support of COVID-19 Patients. CLEWICU is the only device authorized by the FDA to provide early identification of patients who are likely to experience respiratory failure or hemodynamic instability, both potentially common but significant complications associated with COVID-19. from ILTV: Interview with CLEW’s CEO, Gal Salomon

CLEW Receives FDA Emergency Use Authorization (EUA) for its Predictive Analytics Platform in Support of COVID-19 Patients

CLEWICU is the only device authorized by the FDA to provide early identification of patients who are likely to experience respiratory failure or hemodynamic instability, both potentially common but significant complications associated with COVID-19 from CLEW Receives FDA Emergency Use Authorization (EUA) for its Predictive Analytics Platform in Support of COVID-19 Patients

Request a Demo

"*" indicates required fields

Name*